tbuckley/cabot-search huggingface dataset:
671P Postoperative chemoradiation in combination with cetuximab followed by 6-months cetuximab maintenance in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence
Authors: B.F. Tamaskovics, C. Matuschek, J. Haussmann, J. Debus, T. Held, M. Henke, S. Kirste, M. Bamberg, W. Stefan, C. Belka, U. Ganswindt, T. Wiegel, M. Mäurer, V. Budach, M. Stuschke, J. Schipper, E. Boelke, W. Budach
Journal: Annals of Oncology (2022)
980P Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
Authors: A.E. Drilon, J. Chan, J. Sands, D.S.W. Tan, J. Weiss, B. Solomon, Y.J. Kim, M.L. Johnson, T. Puri, M.A. Sarno, S. Kang, V. Soldatenkova, C-W. Duann, S. Szymczak, V. Subbiah, B. Besse
Journal: Annals of Oncology (2022)
681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117
Authors: V. Gruenwald, J. Alt, M. Tometten, M. Haenel, P. Ivanyi, G. Schuch, K. Klinghammer, K. Gutsche, J. Hasenkamp, G. Hapke, M. Mänz, W. Weichert, D.A. Hahn
Journal: Annals of Oncology (2022)
439TiP A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)
Authors: M.G. Fakih, M. Tejani, X. Ren, D. Landes, S. Werneke, K.K. Curtis, J.R. Hecht
Journal: Annals of Oncology (2022)
1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
Authors: I. Bahce, F.L. Schneiders, S. Hashemi, J. Veltman, H. Daniels, M. Fransen, T. Radonic, E. Ulas, I. Houda, N. Barlo, M. Disselhorst, M. van Laren, M. Tiemessen, S. Tarasevych, J.M.M. van Haarst, P. van Tilburg, P. Kunst, A. Moons-Pasic, T.D. de Gruijl, S. Senan
Journal: Annals of Oncology (2022)
715P The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study
Authors: None Z. Xiaoyun, None X. Zhu, X. Feng, None W. Han, M-L. Yan, None F. Xie, None S. Zhang, None Y. Zhang, None X. Jiang, W. Peng, None C. Li, None W. Lu, C. Liu, None Q. Li, W. Chen, None S. Cheng, None T. Wen
Journal: Annals of Oncology (2022)
283MO Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort
Authors: I.C. Glitza, C. Saberian, J. Simon, S. Duncan, R. Amaria, M. Davies, A. Diab, J. Mcquade, S. Patel, H.A. Tawbi, C. Yee, M. Wong, I. McCutcheon, D. Milton, S. Ferguson
Journal: Annals of Oncology (2022)
CN76 Cost effectiveness of high versus low-to-moderate intensity exercise during oncological treatment: The Phys-Can RCT
Authors: A-K. Ax, M. Husberg, B.B. Johansson, I. Demmelmaier, S. Berntsen, K. Sjövall, S. Börjeson, K. Nordin, T. Davidson
Journal: Annals of Oncology (2022)
590P Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study
Authors: V. Tuninetti, E. Ghisoni, S. Pignata, E. Picardo, F. Raspagliesi, C. Andreetta, E. Maldi, G. Artioli, S. Mammoliti, M. Roccio, A. Sikokis, N. Biglia, A. Parisi, V.D. Mandato, C. Carella, G. Cormio, M. Marinaccio, G. Scotto, M. Di Maio, G. Valabrega
Journal: Annals of Oncology (2022)
672P Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results on efficacy and correlative analysis
Authors: I. Vathiotis, J.M. Johnson, L. Harshyne, A. Luginbuhl, J.M. Curry, D. Cognetti, R. Axelrod, V. Bar-Ad, A. Argiris
Journal: Annals of Oncology (2022)
1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
Authors: G. Ruiz de Garibay, B. Roch, P. Garrido Lopez, D. Isla, C. Aguado, A. Callejo Perez, R. Marse Fabregat, M.R. Garcia Campelo, A. Blasco Cordellat, J.M. Sanchez Torres, R. Bernabe Caro, O.J. Juan Vidal, J. De Castro Carpeno, F.F. Franco, I. Ramos Garcia, A. Gomez Rueda, E. Conde Gallego, S. Ponce Aix, L. Paz-Ares, J. Zugazagoitia
Journal: Annals of Oncology (2022)
195P Breast cancer molecular subtypes markers in subpopulations of circulating tumor cells
Authors: E. Grigoryeva, O.E. Savelieva, L. Tashireva, V.V. Alifanov, V. Yakushina, N.A. Tarabanovskaya, N. Cherdyntseva, V. Perelmuter
Journal: Annals of Oncology (2022)
1059P KRAS G12 subtypes with co-mutated TP53, LRP1B, STK11, KEAP1 in lung cancer and their impact on TMB levels, PD-L1 expression and overall survival
Authors: Y. Zhao, X. Wu, H. Tang, Q. Qi, C. Zhang, X. Liu, M. Huang
Journal: Annals of Oncology (2022)
206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications
Authors: P. Tarantino, S.L. Niman, T. Erick, N. Priedigkeit, B. Harrison, A. Giordano, F. Nakhlis, J.R. Bellon, T. Parker, S. Strauss, Q. Jin, T.A. King, B. Overmoyer, G. Curigliano, M. Regan, S. Tolaney, F. Lynce
Journal: Annals of Oncology (2022)
884TiP A phase Ib/II multicenter, randomized, umbrella study evaluating novel treatment combinations in melanoma (MORPHEUS-MELANOMA)
Authors: G.V. Long, R. Amaria, A. Tarhini, P.A. Ascierto, E. Cha, O. Cirovic, D. Cotting, V. Teichgräber, C.U. Blank
Journal: Annals of Oncology (2022)
340P Prediction of relapse in colon cancer patients by machine learning models combining radiomics and deep features extracted from baseline computed tomography
Authors: A. Bueno Gómez, N. Tarazona Llavero, A. Alcolado Jaramillo, F. Gimeno-Valiente, J.A. Carbonell-Asins, M. Huerta, T.C. Fleitas, S. Roselló Keränen, L.M. Candia, D. Roda Perez, P. Moreno Ruiz, A. Jiménez Pastor, A. Alberich-Bayarri, A. Cervantes
Journal: Annals of Oncology (2022)
864P Prognostic impact of MARCO and OAS1 expression in metastatic melanoma patients treated with anti-PD1: A proteomics and transcriptomics retrospective analysis
Authors: D. Mallardo, C. Messner, M. Capone, J. Vowinckel, A. Sorrentino, K. Novy, V. Vanella, K. Kakalacheva-Beeler, S. Warren, P.A. Ascierto
Journal: Annals of Oncology (2022)
196P Molecular profiling to identify recurrent mutations comparing pre and post-neoadjuvant chemotherapy tumour specimens of TNBC patients with residual disease
Authors: J.T. Georgy, A. Singh, D. Sakthi, E. Sigamani, A. Joel, D.B. Thumaty, A.O. John, J.P. Wisely, P. Kumar M, H. Kovilapu, None P. jambunathan, S. Backianathan, J. Chandramohan, M. Therese Manipadam, G. Rebekah, R.T. Chacko, R. Pai
Journal: Annals of Oncology (2022)
824P Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)
Authors: J. Mo, A. Zaremba, A-J. Inderjeeth, P. El Zenaity, A. Li, A. Wicky, N. Della Marta, C. Gaudy Marqueste, A-S. Bohne, L. Festino, C. Chen, S.N. Lo, A. Guminski, O.A. Michielin, W. Xu, C. Lebbe, S.K. Sandhu, L. Zimmer, M.S. Carlino, I. Pires da Silva
Journal: Annals of Oncology (2022)
284MO Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)
Authors: G. Finocchiaro, M. Eoli, F. Farina, B. Gentner, A. Capotondo, E. Anghileri, M. Bruzzone, Q.G. D'Alessandris, A. Franzin, P. Ferroli, F. Gagliardi, F. Legnani, S. Mazzoleni, A. Olivi, R. Pallini, M. Saini, A. Zambanini, L. Naldini, C. Russo, F. Ciceri
Journal: Annals of Oncology (2022)
828P Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study
Authors: C. Berking, E. Livingstone, M. Weichenthal, U. Leiter-Stoppke, J. Remy, T. Eigentler, P. Mohr, F. Kiecker, C. Loquai, D. Debus, R. Gutzmer
Journal: Annals of Oncology (2022)
70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study
Authors: M. De With, J. Knikman, A. Baars, G-J.M. Creemers, H.J. Droogendijk, E. Fiets, A.L.T. Imholz, L.B.J. Valkenburg-van Iersel, F.J.F. Jeurissen, C.M.P.W. Mandigers, R.H.N. Van Schaik, B.J.C. van den Bosch, H. Rosing, J.H. Beijnen, J.J. Swen, H. Gelderblom, J.H.M. Schellens, R.H. Mathijssen, H-J. Guchelaar, A. Cats
Journal: Annals of Oncology (2022)
677P A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): An expansion cohort
Authors: N. Ngamphaiboon, T. Siripoon, S. Lukerak, A. Jinawath, L. Arsa, P. Shantavasinkul, N. Taonam, N. Jinawath, A. Kositwattanarerk, T. Sananmuang, P. Pattaranutaporn, C. Jiarpinitnun
Journal: Annals of Oncology (2022)
491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
Authors: T.A. Yap, K.N. Moore, M. Patel, B.S. Henick, D. Do, A. Iheanacho, H. Zhang, M. Roche, K. Newberry, A. Hsieh, D. Juric
Journal: Annals of Oncology (2022)
542P Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
Authors: K. Song, Y. Ma, N. Li, H. Bu, Y. Huang, C. Jin, H. Wen, S. Feng, H. Zhang, L. Wu
Journal: Annals of Oncology (2022)
745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody
Authors: K.S. Rohrberg, E. Garralda, E. Calvo, V. Moreno Garcia, M. Guidi, D.G. Kraus, C. McIntyre, H. Kao, L. Codarri Deak, F. Michielin, T. Liu, M. Muecke, C. Markert, I. Melero
Journal: Annals of Oncology (2022)
205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials
Authors: D.A. Yardley, Y.S. Yap, H.A. Azim, R.H. De Boer, M. Campone, A. Ring, M. De Laurentiis, J. O'Shaughnessy, J. Cortés, Y. Chattar, A. Thuerigen, J.P. Zarate, A. Nusch
Journal: Annals of Oncology (2022)
878P Improved proteome coverage for cancer plasma-derived extracellular vesicles (pEVs) using high-resolution isoelectric focusing (HiRIEF) LC-MS
Authors: N. Sharma, G. Mermelekas, J. Lehtiö, O.P.B. Wiklander, A. Gorgens, S. Andaloussi, M. Pernemalm, H. Eriksson
Journal: Annals of Oncology (2022)
392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
Authors: V. Moreno Garcia, P.A. Cassier, B. Doger de Spéville, E. Calvo, M.J. De Miguel, R. Garcia-Carbonero, C.A. Gomez-Roca, C. Jungels, None P. Erbs, S. Sainte-Croix, A. Sadoun, K. Bendjama
Journal: Annals of Oncology (2022)
807P Adjuvant anti-PD-1 monotherapy benefit varies across different ethnicities and melanoma subtypes
Authors: X. Bai, S. Gerstberger, B. Park, S. Jung, R. Johnson, N. Yamazaki, D. Ogata, Y. Umeda, C. Li, L. Si, K. Flaherty, Y. Nakamura, K. Namikawa, G.V. Long, A.M. Menzies, D.B. Johnson, R.J. Sullivan, G. Boland, J. Guo
Journal: Annals of Oncology (2022)
692P Copy number alterations and response to radiotherapy + cisplatin vs radiotherapy + cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
Authors: J.L. García, A. Olivares Hernandez, N. Alonso, L.A. Corchete Sánchez, J. Fernandez-Mateos, J. Perez García, M.A. Hernández, R. Seijas Tamayo, R. Mesia Nin, J. Rubió-Casadevall, C. Garcia Giron, L. Iglesias, A. Carral Maseda, J.C. Adansa Klain, M. Taberna Sanz, S. Vazquez, A. Gómez Muñoz, E. del Barco, R. González Sarmiento, J.J. Cruz Hernandez
Journal: Annals of Oncology (2022)
480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)
Authors: P.A. Cassier, C. Terret, A. Voisin, C. Schiffler, A-S. Bidaux, H. Vanacker, L. Eberst, M.W. Lepercq, A. D'Argenio, None M. Bernardin, A. Bouhamama, L. Gilles-Afchain, I. Treilleux, S. Tabone-Eglinger, D. Spaggiari, S. Chabaud, Y. Grinberg-Bleyer, G. Garin, D. Perol, A. Vinceneux
Journal: Annals of Oncology (2022)
636P Development of radiolabelled plerixafor as a theranostic tool for malignant lymphomas
Authors: T. Lakhanpal, J. Shukla, R. Kumar, P. Malhotra, G. Prakash, A. Bal, Y. Rathore, A. Khadwal, None H. Singh, B.R. Mittal
Journal: Annals of Oncology (2022)
55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
Authors: C. Yoo, K-P. Kim, I. Kim, M.J. Kang, J. Cheon, B.W. Kang, H. Ryu, J. Jeong, J.S. Lee, K.W. Kim, B-Y. Ryoo, G.K. Abou-Alfa
Journal: Annals of Oncology (2022)
650O A phase II study of nivolumab for high-risk oral leukoplakia
Authors: G.J. Hanna, A. Villa, R. Shi, A. O'Neill, M. Liu, C.T. Quinn, R.K. Curtin, M. Flynn, N.S. Treister, H.Y. Sroussi, P. Vacharotayangul, L.A. Goguen, D.J. Annino, E.M. Rettig, V.Y. Jo, K. Wong, R. Uppaluri, R. Haddad, S-B. Woo
Journal: Annals of Oncology (2022)
138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
Authors: J.M. Bartlett, K. Xu, J. Wong, G. Pond, Y. Zhang, M. Spears, R. Salunga, E. Mallon, K.J. Taylor, A. Hasenburg, C. Markopoulos, L.Y. Dirix, C. Seynaeve, C. van de Velde, D. Rea, C.A. Schnabel, K. Treuner, J. Bayani
Journal: Annals of Oncology (2022)
575P Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study
Authors: R.D. Morgan, A.R. Clamp, B. Barnes, H. Schlecht, L. Yarram-Smith, Y. Wallis, S. Morgan, M. Valganon, E. Hudson, S. McKenna, S. Sundar, S. Nicum, J.D. Brenton, R. Kristeleit, S. Banerjee, I. McNeish, J.A. Ledermann, S. Taylor, G. Evans, G.C. Jayson
Journal: Annals of Oncology (2022)
883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Authors: J. Chesney, T. Wise-Draper, A.A. Sarnaik, F. Graf Finckenstein, P. Hari, M. Jagasia, A. Desai, A. Suzuki, X. Wu, A. Betof Warner
Journal: Annals of Oncology (2022)
CN61 Patients’ experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Interview results
Authors: L. Matthews, M. Teoh, S. May, C. Zammit, D. Bloomfield, M. Kothari, D. Betal, R. Santos, E. Stewart, J. Finlay, K. Nicholson, D. Elwell-Sutton, F. McKinna, H. Gage, S. Bell, V.A. Jenkins
Journal: Annals of Oncology (2022)
800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma
Authors: D. Zara, B. Pastò, M. Garutti, M. Bartoletti, L. Palmero, E. Bertoli, C. Noto, L. Cucciniello, F. Totaro, M. Rizzetto, T. Pivetta, A. Membrino, A. Freschi, S. Bolzonello, F. Puglisi
Journal: Annals of Oncology (2022)
756P Glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model
Authors: A. Arulanandam, H. Potu, V. Khairnar, D. Zou, M. Triggiano, N. Dilmac, L. Lin, H-M. Chang, A. Welch, O. Mandelboim, Y. Ilan, D. Teper, S. Frankel, J. Kadouche, W. Li
Journal: Annals of Oncology (2022)
60P A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report
Authors: X. Wang, S. Fu, K. Zheng, G. Cao, L. Xu, R. Yang, X. Zhu, P. Liu, S. Gao, H. Xu, J. Guo, H. Chen, K. Wang, J. Li, J. Zhou, X. Zhang, C. Hao, B. Xing, L. Shen
Journal: Annals of Oncology (2022)
149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data
Authors: O. Rotem, I. Peretz, M. Leviov, I. Kuchuk, A. Itay, M. Tokar, S. Paluch-Shimon, O. Maimon, R. Yerushalmi, K. Drumea, E. Evron, A. Sonnenblick, E. Nili Gal Yam, H. Goldvaser, S.G. Yosef, R. Merose, A. Bareket-Samish, L. Soussan-Gutman, S. Stemmer
Journal: Annals of Oncology (2022)
923P Molecular classification of cancers of unknown primary expands and refines treatment options
Authors: D.J. George, E. Moore, G.C. Blobe, N. DeVito, B.A. Hanks, M.R. Harrison, C.J. Hoimes, J. Jia, M. Morse, P. Jayaprakasan, A. MacKelfresh, H. Mulder, K. Beauchamp, J. Michuda, M.C. Stumpe, E. Perakslis, T. Taxter
Journal: Annals of Oncology (2022)
845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
Authors: J.M. Kirkwood, Y. Zakharia, D. Davar, E. Buchbinder, T. Medina, A. Daud, A. Ribas, B. Chmielowski, J.J. Niu, G.T. Gibney, K.A. Margolin, A.J. Olszanski, I. Mehmi, T. Sato, M. Shaheen, L. Zhao, D. Bobilev, A.M. Krieg, J. Wooldridge, M. Milhem
Journal: Annals of Oncology (2022)
49P Identifying peripheral immune predictors of durable clinical response to PD-L1 blockade in small cell lung cancer
Authors: M.A. Galindo Campos, M. Hardy-Werbin, A. Rios Hoyo, J. Gibert, A. Rossell, S. Gonzalez, P.F. Simoes da Rocha, R. Del Rey-Vergara, L. Masfarré, N. Navarro Gorro, A. Taus Garcia, A. Rovira, E. Arriola
Journal: Annals of Oncology (2022)
237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
Authors: F. Brasó-Maristany, G. Griguolo, N. Chic, L. Pare Brunet, P. Galván, M.V. Dieci, F. Miglietta, T. Giarratano, O. Martínez-Sáez, M. Marin, M.J. Vidal Losada, B. Adamo, M. Munoz, A. Vivancos, P. Villagrasa Gonzalez, J. Parker, C.M. Perou, P.F. Conte, A. Prat, V. Guarneri
Journal: Annals of Oncology (2022)
906P A pilot study of a lung cancer screening program with low-dose computed tomography in high-risk individuals in Greece
Authors: S. Lampaki, E. Fountzilas, A. Vagionas, I. Filippou, G. Mountzios, G. Koliou, N. Pastelli, T. Karaiskos, D. Spyratos
Journal: Annals of Oncology (2022)
53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
Authors: A. Vogel, P. Wenzel, G. Folprecht, P. Schütt, H. Wege, A. Kretzschmar, L. Jacobasch, N. Ziegenhagen, S. Boeck, S. Kanzler, J. Mohm, S. Belle, D. Pink, T.O. Götze, E. Goekkurt, U. Graeven, M. Schaaf, M. Kirstein, A. Saborowski
Journal: Annals of Oncology (2022)
207P Comparison of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors in the second-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer: A network meta-analysis
Authors: Y. Fan, D. Ji, Y. Luo, J. Wang, S. Chen, B. Lan, B. Xu
Journal: Annals of Oncology (2022)
1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC)
Authors: F.G. Dall'Olio, M. Lerousseau, G. Roman, F-X. Danlos, M. Aldea, N. Chaput-Gras, D. Planchard, F. Barlesi, T. Hulett, A. Marabelle, B. Besse
Journal: Annals of Oncology (2022)
704TiP SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Authors: M. Patel, P.A. Ascierto, F. Thistlethwaite, D.R. Adkins, V. Meucci Villaflor, D. Galizia, L. Calabro, M. Di Maio, C. D'Ambrosio, A. Bertolini, A. Damato, C. Deantonio, Y. Yang, D. Kurup, G. Abbadessa
Journal: Annals of Oncology (2022)
893P Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
Authors: I. Angelioudaki, M. Theochari, E. Koniaris, A. Kataki, L. Stoupis, A. Mitrousias, A-G. Tzingounis, N. Dafnios, G. Zografos, G. Kafiri, M. Konstadoulakis
Journal: Annals of Oncology (2022)
1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
Authors: M.E. Buyse, F. Montestruc, J-C. Chiem, V. Deltuvaite-Thomas, S. Salvaggio, M.R. Garcia Campelo, M. Cobo Dols, E. Quoix, A-C. Madroszyk Flandin, F. Cappuzzo, G. Romano, S. Viteri Ramirez, W. Schuette, A. Zer, S. Comis, B. Vasseur, R. Dziadziuszko, G. Giaccone, B. Besse, E. Felip
Journal: Annals of Oncology (2022)
881TiP NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma
Authors: L. Mao, X. Bai, X. Wei, J. Dai, C-L. Cui, Z. Chi, X. Sheng, B. Lian, X. Wang, T. Bixia, L. Si, J. Guo
Journal: Annals of Oncology (2022)
622MO An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
Authors: E. Lee, Y. Lim, S. Lee, S. Park, H. Park, Y. Koh, D. Shin, J. Won
Journal: Annals of Oncology (2022)
317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
Authors: C. Gallois, Q. Shi, J. Meyers, T. André, T.J. Iveson, A.F. Sobrero, S. Alberts, A. de Gramont, J. Meyerhardt, A.F. Shields, T. Georges, H.J.E-V. Schmoll, I. Souglakos, R. Kerr, S. Lonardi, G. Yothers, T. Yoshino, R. Goldberg, J. Taieb, D. Papamichael
Journal: Annals of Oncology (2022)
91P Liquid biopsy, a tool to detect genetic alterations with therapeutic impact in international patients: Prospective data on 47 patients from Gustave Roussy
Authors: T.S. Assi, T. Ibrahim, C. Chahine, N. Lezghed, N. Masri, E. Rouleau, O. Caron, A. Le Cesne
Journal: Annals of Oncology (2022)
145P Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: A TRAIN-2 sub study
Authors: M.C. Liefaard, A. van der Voort, M. van Seijen, J. Sanders, S. Vonk, L. de Munck, A.E. van Leeuwen-Stok, H. Horlings, R.F. Salgado, E. Lips, G.S. Sonke
Journal: Annals of Oncology (2022)
634P Real-world (RW) health-related quality of life (QoL) in patients (pts) with follicular lymphoma (FL): Comparisons by line of therapy (LOT) and region (Europe vs United States (US))
Authors: P.C. Johnson, A.L. Bailey, N. Milloy, E. Clayton, R. Quek, Q. Ma
Journal: Annals of Oncology (2022)
797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm
Authors: I.L.M. Reijers, A.M. Menzies, J.M. Versluis, P. Dimitriadis, M. Wouters, R.P.M. Saw, M.C. Klop, T.E. Pennington, W. Van Houdt, L.J.W. Bosch, S. Cornelissen, M.I. Lopez-Yurda, L. Grijpink-Ongering, R. Rawson, A.J. Spillane, R.A. Scolyer, B. van de Wiel, A.C.J. van Akkooi, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2022)
858P Automated detection of melanoma: Comparing a convolutional neural network (CNN) approach with an algorithm assessing disorder in the pattern of pigmented lesions, intended to mimick onco-dermatologists' visual analysis
Authors: J. Monnier, A.C. Gouabou Foahom, M. Serdi, J. Collenne, R. Iguernaissi, C. Gaudy Marqueste, J-L. Damoiseaux, J.J. Grob, D. Merad
Journal: Annals of Oncology (2022)
974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)
Authors: S. Novello, D.M. Kowalski, A. Luft, M. Gumus, D. Vicente Baz, J. Mazieres, J.R. Rodriguez Cid, A. Tafreshi, Y. Cheng, K.H. Lee, A. Golf, S. Sugawara, A.G. Robinson, B. Halmos, E. Jensen, P.O. Schwarzenberger, M.C. Pietanza, L. Paz-Ares
Journal: Annals of Oncology (2022)